scholarly journals Primary Hepatic Lymphoma in a Patient with Rheumatoid Arthritis Treated with Methotrexate

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Goichi Tatsumi ◽  
Naoya Ukyo ◽  
Hirokazu Hirata ◽  
Mitsuru Tsudo
Keyword(s):  
Rheumatoid Arthritis ◽  
B Cell Lymphoma ◽  
Japanese Woman ◽  
Rapid Progression ◽  
Low Grade ◽  
Primary Hepatic Lymphoma ◽  
Barr Virus ◽  
Elevated Liver Enzymes ◽  
Old Japanese ◽  
Epstein Barr

Primary hepatic lymphoma (PHL) has rarely been reported in patients with immunosuppression. We herein describe a case of Epstein-Barr virus- (EBV-) positive PHL in a 67-year-old Japanese woman receiving methotrexate (MTX) treatment for rheumatoid arthritis (RA). The patient, who had been receiving MTX therapy for more than 6 years, presented with low-grade fever and abdominal pain. Initial laboratory tests showed mildly elevated liver enzymes with normal levels of alpha-fetoprotein and carcinoembryonic antigen, and computed tomography scans revealed multiple hepatic tumors with no lymph-node swelling. Examination of liver specimens obtained via ultrasonography-guided needle biopsy indicated EBV-positive diffuse large B cell lymphoma; therefore, she was diagnosed with PHL. MTX was discontinued, and she was carefully monitored thereafter owing to the prolonged history of MTX administration for RA. Rapid progression of PHL was observed; therefore 10 days after the PHL diagnosis, she received 6 cycles of R-THP-COP (rituximab, cyclophosphamide, pirarubicin, vincristine, and prednisolone) therapy and achieved complete remission for more than 1 year. Although MTX-associated lymphoproliferative disorders often show remission after withdrawal of MTX, early diagnosis and treatment are essential for PHL in patients with RA treated with MTX, because of the aggressive nature of the disease.

Clinicopathologic and Genetic Profile of Intracranial Marginal Zone Lymphoma: A Primary Low-Grade CNS Lymphoma That Mimics Meningioma

2005 ◽  
Vol 23 (24) ◽  
pp. 5718-5727 ◽  
Author(s):  
Pang-hsien Tu ◽  
Caterina Giannini ◽  
Alexander R. Judkins ◽  
Jason M. Schwalb ◽  
Richard Burack ◽  
...  
Keyword(s):  
Marginal Zone ◽  
Primary Cns Lymphoma ◽  
B Cell Lymphoma ◽  
Cns Lymphoma ◽  
Genetic Profile ◽  
Low Grade ◽  
Barr Virus ◽  
Genetic Features ◽  
Trisomy 3 ◽  
Epstein Barr

Purpose Although rare overall, marginal zone B-cell lymphoma (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature. The aim of this study is to elucidate the biology and genetic features of this unusual tumor. Patients and Methods Fifteen CNS MZBCLs were studied clinically, pathologically, and genetically, including fluorescent in situ hybridization analyses with commercially available MALT1 and IgH break-apart and centromere 3, 7, 12, and 18 probes. Results CNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma. Ten patients with 1 to 7.6 years of follow-up after diagnosis showed no evidence of disease after radiation and/or chemotherapy. Like MZBCLs outside of the CNS, they consisted of CD20+, CD3− small B lymphocytes with varying degrees of plasmacytic differentiation and predominantly κ light-chain restriction (78%). Lymphoid follicles with follicular colonization were seen in three patients and deposition of amyloid was noted in samples from two patients, one of which was tumefactive. Neither Bcl-6 protein nor Epstein-Barr virus–encoded RNA was expressed. Trisomy 3 was detected in six of 12 patients, with no rearrangements of MALT1 or IgH and no trisomies of 7, 12, or 18 detected. Conclusion Our data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass. Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.

Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report

2008 ◽  
Vol 1 (3) ◽  
pp. 105-109 ◽  
Author(s):  
Tomonori Sumida ◽  
Yasuhiko Kitadai ◽  
Hiroshi Masuda ◽  
Kei Shinagawa ◽  
Miwako Tanaka ◽  
...  
Keyword(s):  
Case Report ◽  
B Cell ◽  
Epstein Barr Virus ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Rapid Progression ◽  
Barr Virus ◽  
Large B Cell Lymphoma ◽  
Epstein Barr ◽  
Large B Cell

scholarly journals Epstein–Barr Virus-Positive Mucocutaneous Ulcer: A Unique and Curious Disease Entity

2021 ◽  
Vol 22 (3) ◽  
pp. 1053
Author(s):  
Tomoka Ikeda ◽  
Yuka Gion ◽  
Yoshito Nishimura ◽  
Midori Filiz Nishimura ◽  
Tadashi Yoshino ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Malignant Lesion ◽  
B Cell Lymphoma ◽  
Clinicopathological Characteristics ◽  
Good Prognosis ◽  
World Health ◽  
Low Grade ◽  
Barr Virus ◽  
Epstein Barr ◽  
Health Organization

Epstein–Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) was first described as a lymphoproliferative disorder in 2010. EBVMCU is a unifocal mucosal or cutaneous ulcer that often occurs after local trauma in patients with immunosuppression; the patients generally have a good prognosis. It is histologically characterized by proliferating EBV-positive atypical B cells accompanied by ulcers. On the basis of conventional pathologic criteria, EBVMCU may be misdiagnosed as EBV-positive diffuse large B-cell lymphoma or other lymphomas. However, its prognosis differs from that of EBV-associated lymphomas, in that patients with EBVMCU frequently show spontaneous regression or complete remission without chemotherapy. Therefore, EBVMCU is now recognized as a low-grade malignancy or a pseudo-malignant lesion. Avoiding unnecessary chemotherapy by distinguishing EBVMCU from other EBV-associated lymphomas will reduce the burden and unnecessary harm on patients. On the basis of these facts, EBVMCU was first described as a new clinicopathological entity by the World Health Organization in 2017. In this review, we discuss the clinicopathological characteristics of previously reported EBVMCU cases, while focusing on up-to-date clinical, pathological, and genetic aspects.

Transformation of Small B-Cell Lymphoma Into Large Cell CD30+, CD4+, Epstein-Barr Virus–Negative Lymphoma

2014 ◽  
Vol 138 (8) ◽  
pp. 1101-1105 ◽  
Author(s):  
Aaron C. Shaver ◽  
Ly Ma ◽  
Cindy Vnencak-Jones ◽  
Roland S. Schwarting ◽  
Kristina J. Fasig ◽  
...  
Keyword(s):  
B Cell ◽  
Epstein Barr Virus ◽  
Cell Lymphoma ◽  
Relevant Literature ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
B Cell Lymphomas ◽  
Barr Virus ◽  
Wide Range ◽  
Epstein Barr

We report here 2 separate cases in which patients with known low-grade B-cell lymphomas presented with transformed lesions that were CD30+, CD4+, Epstein-Barr virus negative, and negative or focally weak for a wide range of B-cell, T-cell, and histiocytic/dendritic cell markers. In each case the transformed lymphoma possessed an identical pattern of immunoglobulin heavy chain and/or BCL2 rearrangement to the corresponding original low-grade B-cell lymphoma, confirming their identity as transformed B-cell lymphoma. A review of the relevant literature reveals that, to our knowledge, no transformed B-cell lymphomas with this immunophenotype have been previously reported, which creates the opportunity for potential errors of diagnosis. These cases highlight the importance of correlation with the patient's history and with molecular genetic results in rendering an accurate diagnosis.

Epstein-Barr Virus–Associated High-Grade B-Cell Lymphoma of Mucosal-Associated Lymphoid Tissue in a 9-Year-Old Boy

2000 ◽  
Vol 124 (10) ◽  
pp. 1520-1524 ◽  
Author(s):  
Jianguo Tao ◽  
Leonard Kahn
Keyword(s):  
B Cell ◽  
Malt Lymphoma ◽  
Lymphoid Tissue ◽  
Epstein Barr Virus ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Renal Tubules ◽  
High Grade ◽  
Barr Virus ◽  
Epstein Barr

Abstract We report an unusual case of Epstein-Barr virus (EBV)-associated mucosal-associated lymphoid tissue (MALT) lymphoma involving the lungs, kidneys, and axillary lymph nodes in a child with congenital hypoadrenalism and panhypopituitarism. The patient presented with an aggressive clinical course and histologic evolution. Initial biopsies (1994) of the lung and kidney revealed histologic features of low-grade B-cell MALT lymphoma with lymphoepithelial lesions within the renal tubules and bronchial epithelium. Subsequent biopsies (1996, 1997, and 1999) revealed progressively greater cytologic atypia, polymorphism, and necrosis; an increased mitotic rate; and a preponderance of large cells, indicative of progression from a low-grade to a high-grade MALT lymphoma. Immunophenotyping of the lung and lymph node lesions revealed identical surface marker profiles: cells were CD19+, CD20+, immunoglobulin (Ig) G+, κ+, λ−, CD5−, CD10−, CD23−, and IgM−, and also negative for T-cell markers. Genotypic analysis demonstrated the presence of immunoglobulin heavy chain rearrangement and monoclonality of EBV in the lung lesion by Southern blot hybridization and polymerase chain reaction (PCR). The clinicopathologic features suggest that these lesions might represent an immunosupression-related continuum of low-grade to high-grade MALT lymphomas. Infection with EBV may have contributed to this tumor's aggressive clinical and histologic evolution.

Sign in / Sign up

Export Citation Format

Share Document